• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    June 14, 2024 - FDA Roundup: June 14, 2024

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MMSI alert in real time by email
    For Immediate Release:
    June 14, 2024

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the rule.
    • Today, the FDA announced a recall initiated by Merit Medical Systems, Inc. in direct response to the Jiangsu Shenli Medical Production Co Ltd. recall to stop using its unauthorized plastic syringes. Merit includes the affected Jiangsu Shenli syringes in multiple kits. A timeline and summary of activities related to this issue, including recalls, is provided in FDA Actions. The FDA recommendations have not changed. We will continue our efforts to evaluate problems with syringes made in China and keep the public informed as new or additional information becomes available.
    • On Thursday, the FDA announced the issuance of warning letters to six online retailers for selling unauthorized e-liquid products from the Bad Drip brand that imitate prescription drug bottles. The retailers were also warned for selling unauthorized flavored, disposable e-cigarettes, including those under the brand names Funky Republic and HQD. 
    • On Thursday, the FDA granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy. The most common (>20%) adverse reactions were dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, and nausea. Full prescribing information for Augtyro will be posted on Drugs@FDA.
    • On Thursday, the FDA posted a CDER Conversation with Robert Ball, M.D., M.P.H., ScM, Deputy Director of CDER’s Office of Surveillance and Epidemiology. Dr. Ball explains the Emerging Drug Safety Technology Meeting program and the application of artificial intelligence (AI) in pharmacovigilance (PV) based on his experience of more than a decade researching and developing AI systems in PV. For more information, read the CDER Conversation: Emerging Drug Safety Technology Meeting Program.
    • On Thursday, the FDA updated its advice to manufacturers of COVID-19 vaccines (2024-2025 Formula). The FDA initially advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States beginning in fall 2024 should be monovalent JN.1 vaccines.  Based on the most current available data, along with the recent rise in cases of COVID-19 in areas of the country, the agency has further determined that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 Formula) is the KP.2 strain, if feasible. This change is intended to ensure that the COVID-19 vaccines (2024-2025 Formula) more closely match circulating SARS-CoV-2 strains. The FDA has communicated this change to the manufacturers of the licensed and authorized COVID-19 vaccines. The agency does not anticipate that a change to KP.2 will delay the availability of the vaccines for the United States.
    • On Thursday, the FDA announced the Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles, published jointly by the FDA, Health Canada, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency. For a machine learning-enabled medical device, effective transparency helps ensure that information that could impact patient risks and outcomes is communicated to all the people who could be interacting with the medical device, including health care providers, payors, and others, to help make informed decisions. Transparency across health care is an international priority and the FDA will continue to collaborate with international partners in this area.
    • On Wednesday, the FDA granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Selpercatinib received accelerated approval for this indication for patients 12 years of age and older in 2020. The most common adverse reactions (≥25%) were edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, and headache.  Full prescribing information for Retevmo will be posted on Drugs@FDA.
    • On Tuesday , the United States District Court for the District of Colorado entered a consent decree of permanent injunction against Boosted LLC (who also does business as Boosted E-Juice, Boosted, and Live Boosted) and Cory Vigil, owner of Boosted LLC. The consent decree prohibits Boosted LLC and Mr. Vigil from manufacturing, selling, or distributing any new tobacco products until they meet certain requirements. According to the complaint filed by the U.S. Department of Justice on FDA’s behalf, defendants were previously warned they were in violation of the Federal Food, Drug, and Cosmetic Act’s premarket review requirements for manufacturing, selling, and distributing new tobacco products by failing to first obtain marketing authorization from FDA.
    • On Tuesday, the FDA posted warning letters to four companies marketing the unapproved animal drug toltrazuril to treat conditions like coccidiosis and equine protozoal myeloencephalitis (EPM). The companies included All Things Bunnies Inc., Linessa Farms LLC, TotalTotrazuril.com and Toltrazuril Shop. 
    • On Tuesday, the FDA approved phenylpropanolamine hydrochloride chewable tablets for the control of urinary incontinence due to a weakening of the muscles that control urination (urethral sphincter hypotonus) in dogs. This is the first generic phenylpropanolamine hydrochloride chewable tablets for dogs. Phenylpropanolamine Hydrochloride chewable tablets contain the same active ingredient (phenylpropanolamine hydrochloride) in the same concentration and dosage form as the approved brand name drug product, Proin chewable tablets, which were first approved on Aug. 4, 2011.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

     
    Get the next $MMSI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MMSI
    $BMY

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Merit Medical Systems Inc.
    $MMSI
    3/28/2025$120.00Overweight
    Analyst
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    Merit Medical Systems Inc.
    $MMSI
    12/11/2024$103.00 → $120.00Equal Weight → Overweight
    Wells Fargo
    Bristol-Myers Squibb Company
    $BMY
    12/10/2024$63.00Neutral
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    11/15/2024Peer Perform
    Wolfe Research
    Bristol-Myers Squibb Company
    $BMY
    11/13/2024Neutral → Outperform
    Daiwa Securities
    More analyst ratings

    $MMSI
    $BMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Chief Strategy Officer Shibutani Hiroshi Chris

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      7/2/25 5:07:18 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Arduini Peter J

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      7/1/25 5:52:19 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mcmullen Michael R.

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      7/1/25 5:50:27 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MMSI
    $BMY
    SEC Filings

    See more
    • SEC Form 11-K filed by Merit Medical Systems Inc.

      11-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      6/27/25 4:22:13 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:25:42 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:24:57 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MMSI
    $BMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/21/25 7:09:34 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/19/25 7:19:54 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MMSI
    $BMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merit Medical Names Martha Aronson as New President and Chief Executive Officer

      Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today the appointment of Martha Aronson as Merit's new President and Chief Executive Officer, effective October 3, 2025. Fred P. Lampropoulos will remain as Chairman of the Board, President and CEO of Merit through October 3, 2025. Upon Ms. Aronson's appointment, Mr. Lampropoulos will continue to serve as Chairman of the Board. "I am pleased to welcome Martha to Merit," said Mr.

      7/7/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025

      SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using th

      7/3/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

      Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access Only about 2 in 10 eligible patients currently receive cell therapy treatment; today's announcement will reduce unnecessary barriers for patients and providers Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma® (idecabtagene vi

      6/26/25 10:05:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MMSI
    $BMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on Merit Medical with a new price target

      Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00

      3/28/25 8:20:21 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    $BMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MMSI
    $BMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $MMSI
    $BMY
    Financials

    Live finance-specific insights

    See more
    • Merit Medical Names Martha Aronson as New President and Chief Executive Officer

      Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today the appointment of Martha Aronson as Merit's new President and Chief Executive Officer, effective October 3, 2025. Fred P. Lampropoulos will remain as Chairman of the Board, President and CEO of Merit through October 3, 2025. Upon Ms. Aronson's appointment, Mr. Lampropoulos will continue to serve as Chairman of the Board. "I am pleased to welcome Martha to Merit," said Mr.

      7/7/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025

      SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using th

      7/3/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Bristol Myers Squibb Announces Dividend

      Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 2, 2025, to stockholders of record at the close of business on August 5, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, de

      6/17/25 4:16:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MMSI
    $BMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merit Medical Systems Inc.

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      11/14/24 11:05:03 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      2/13/24 5:09:38 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      2/12/24 5:32:43 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care